Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Radiation therapists shortage in France: Organizational consequences and difficulties in deploying new missions and/or tasks delegation].
Bourgier C, Boisbouvier S, Bayart É, Chamois J, Clavère P, Corbin S, De Oliveira A, Hannoun-Lévi JM, Hasbini A, Geffroy-Hulot C, Le Tallec P, Monpetit É, Santini JJ. Bourgier C, et al. Among authors: hasbini a. Cancer Radiother. 2023 Sep;27(6-7):577-582. doi: 10.1016/j.canrad.2023.07.007. Epub 2023 Aug 16. Cancer Radiother. 2023. PMID: 37596123 French.
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
Taamma A, Fandi A, Azli N, Wibault P, Chouaki N, Hasbini A, Couteau C, Armand JP, Cvitkovic E. Taamma A, et al. Among authors: hasbini a. Cancer. 1999 Oct 1;86(7):1101-8. doi: 10.1002/(sici)1097-0142(19991001)86:7<1101::aid-cncr2>3.0.co;2-r. Cancer. 1999. PMID: 10506692 Clinical Trial.
Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky MC, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Gery B, Zawadi A, Tourani JM, Khoury C, Henry AR, Hasbini A, Guichard F, Borel C, Meert N, Guillet P, Calais MH, Garaud P, Bourhis J. Geoffrois L, et al. Among authors: hasbini a. J Clin Oncol. 2018 Nov 1;36(31):3077-3083. doi: 10.1200/JCO.2017.76.2591. Epub 2018 Jul 17. J Clin Oncol. 2018. PMID: 30016178
[Ductal carcinoma in situ: role of the boost].
Azria D, Auvray H, Barillot I, Baumann P, Benyoucef A, Bons-Rosset F, Bontemps P, Bourgier C, Breton-Callu C, Cowen D, Cretin J, Delalande B, Denis F, Ellis S, Gaci Z, Hannoun-Lévy JM, Hasbini A, Hennequin C, Lagrange JL, Lartigau E, Latorzeff I, Le Blanc-Onfroy M, Lecouillard I, Lemanski C, Levy C, Maingon P, Marchal C, Monnier A, Pradier O, Racadot S, Romestaing P, Serin D, Simon JM, Teyssier E, Tallet A, Tolédano A, Belkacémi Y. Azria D, et al. Among authors: hasbini a. Cancer Radiother. 2008 Nov;12(6-7):571-6. doi: 10.1016/j.canrad.2008.07.005. Epub 2008 Aug 13. Cancer Radiother. 2008. PMID: 18703372 Review. French.
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Voog E, Campillo-Gimenez B, Elkouri C, Priou F, Rolland F, Laguerre B, Elhannani C, Merrer J, Pfister C, Sevin E, L'Haridon T, Hasbini A, Moise L, Le Rol A, Malhaire JP, Delva R, Vauléon E, Cojocarasu O, Deguiral P, Cumin I, Cheneau C, Schlürmann F, Delecroix V, Boughalem E, Mollon D, Ligeza-Poisson C, Abadie-Lacourtoisie S, Monpetit E, Chatellier T, Desclos H, Coquan E, Joly F, Tessereau JY, Dupuy S, Déniel Lagadec D, Marhuenda F, Grudé F. Voog E, et al. Among authors: hasbini a. Int J Cancer. 2020 Mar 15;146(6):1643-1651. doi: 10.1002/ijc.32578. Epub 2019 Aug 1. Int J Cancer. 2020. PMID: 31318983
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers].
Latorzeff I, Sargos P, Créhange G, Belkacémi Y, Azria D, Hasbini A, Dubergé T, Toledano A, Graff-Cailleaud P, Chapet O, Hennequin C, de Crevoisier R, Supiot S, Pasquier D. Latorzeff I, et al. Among authors: hasbini a. Cancer Radiother. 2020 Apr;24(2):143-152. doi: 10.1016/j.canrad.2019.06.018. Epub 2020 Feb 11. Cancer Radiother. 2020. PMID: 32057646 Review. French.
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.
Belkacemi Y, Latorzeff I, Hasbini A, Coraggio G, Pasquier D, Toledano A, Hennequin C, Bossi A, Chapet O, Crehange G, Guerif S, Duberge T, Allouache N, Clavere P, Gross E, Supiot S, Azria D, Bolla M, Sargos P. Belkacemi Y, et al. Among authors: hasbini a. Cancer Radiother. 2020 Dec;24(8):892-897. doi: 10.1016/j.canrad.2020.03.014. Epub 2020 Nov 2. Cancer Radiother. 2020. PMID: 33144063 Review.
[Survey by SFRO, SNRO and AFPPE about the evolution of the radiation therapist profession in France].
Boisbouvier S, Bayart É, Chamois J, Clavère P, Corbin S, De Oliveira A, Geffroy-Hulot C, Hannoun-Lévi JM, Hasbini A, Le Tallec P, Monpetit É, Santini JJ, Bougier C. Boisbouvier S, et al. Among authors: hasbini a. Cancer Radiother. 2023 Dec;27(8):712-717. doi: 10.1016/j.canrad.2023.07.013. Epub 2023 Oct 25. Cancer Radiother. 2023. PMID: 37891038 French.
49 results